| Literature DB >> 27401327 |
Qizhi Hu1, Cristianne J F Rijcken2, Ethlinn van Gaal2, Paul Brundel2, Hana Kostkova3, Tomas Etrych3, Benjamin Weber4, Matthias Barz4, Fabian Kiessling5, Jai Prakash6, Gert Storm7, Wim E Hennink8, Twan Lammers9.
Abstract
To optimally exploit the potential of (tumor-) targeted nanomedicines, platform technologies are needed in which physicochemical and pharmaceutical properties can be tailored according to specific medical needs and applications. We here systematically customized the properties of core-crosslinked polymeric micelles (CCPM). The micelles were based on mPEG-b-pHPMAmLacn (i.e. methoxy poly(ethylene glycol)-b-poly[N-(2-hydroxypropyl) methacrylamide-lactate]), similar to the block copolymer composition employed in CriPec® docetaxel, which is currently in phase I clinical trials. The CCPM platform was tailored with regard to size (30 to 100nm), nanocarrier degradation (1month to 1year) and drug release kinetics (10 to 90% in 1week). This was achieved by modulating the molecular weight of the block copolymer, the type and density of the crosslinking agent, and the hydrolytic sensitivity of the drug linkage, respectively. The high flexibility of CCPM facilitates the development of nanomedicinal products for specific therapeutic applications.Entities:
Keywords: Core-crosslinking; Drug release; Drug targeting; Nanomedicine; Polymeric micelles
Mesh：
Substances：
Year: 2016 PMID： 27401327 DOI： 10.1016/j.jconrel.2016.07.012
Source DB: PubMed Journal: J Control Release ISSN： 0168-3659 Impact factor: 9.776